Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Feb 27, 2024, after the close
10-K filed Feb 28, 2024, 59 days after period end · 0000950170-24-021473
| Metric | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $231.04M | $136.49M | $130.76M | $121.01M |
| Net Income | $45.80M | -$41.73M | -$43.09M | -$66.76M |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| EPS Diluted | $0.28 | -$0.26 | -$0.27 | — |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
